Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-29
DOI
10.1038/s41401-021-00652-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
- (2019) Miroslav Boudny et al. HAEMATOLOGICA
- Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies
- (2019) Lexian Tong et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
- (2018) Kent W. Mouw et al. BRITISH JOURNAL OF CANCER
- DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer
- (2018) Yunxiao Meng et al. CANCER LETTERS
- NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling
- (2018) Zejun Fang et al. CANCER LETTERS
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia
- (2018) Kamal Chamoun et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis
- (2017) Fabian Schuler et al. Nature Communications
- c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
- (2016) Hongyan Liu et al. CLINICAL CANCER RESEARCH
- CHK1 as a therapeutic target to bypass chemoresistance in AML
- (2016) Laure David et al. Science Signaling
- CHK1 as a therapeutic target to bypass chemoresistance in AML
- (2016) Laure David et al. Science Signaling
- c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
- (2015) Aijun Shen et al. CANCER RESEARCH
- Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer
- (2015) Nouf Alsubhi et al. Molecular Oncology
- Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
- (2014) Christopher Bryant et al. Molecular Cancer
- Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors
- (2014) W-T Wang et al. ONCOGENE
- CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress
- (2014) L M Sarmento et al. ONCOGENE
- MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells
- (2012) W.-J. Wang et al. CANCER RESEARCH
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells
- (2011) A. Hoglund et al. CLINICAL CANCER RESEARCH
- Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis
- (2011) L M Tho et al. ONCOGENE
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
- (2011) K. A. Cole et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search